Research
Hormonal
GLP-1RA use in patients with metabolically unhealthy obesity (MUHO) is associated with a significantly lower risk of mortality (HR 0.580) compared to non-use.
Clinicians may consider GLP-1RAs for reducing mortality risk in MUHO patients.
StrongSupportsmedium confidence
GLP-1RA use in MUHO was associated with a significantly lower risk of mortality (HR 0.580 [95% CI, 0.566-0.595])
Why this rating
Based on a large cohort study design.
Source
<scp>GLP</scp> ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
Tommaso Bucci et al. · Diabetes Obesity and Metabolism · 2025
cohort · n=2983151Cited 11×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →